All In Biotech

Drug Trial Radar · NCT00313313

A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone

Last checked: Nov 20, 2026Latest source record: May 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

768

Actual

Start

Apr 2006

Primary completion

Sep 2007

Study completion Sep 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 77 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes

Conditions

  • Diabetes

Interventions

  • SaxagliptinDrug

    Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])

  • SaxagliptinDrug

    Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).

  • GlyburideDrug

    Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)

  • PlaceboDrug

    Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)

  • GlyburideDrug

    Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)

  • MetforminDrug

    Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24Time frame: Baseline, Week 24

Locations

115 sites in 13 countries. Site status is shown where the registry gives one.

  • Reserach Solutions, Llc

    Jonesboro, Arkansas

  • Searcy Medical Center

    Searcy, Arkansas

  • Stewart Medical Group

    Alhambra, California

  • Southland Clinical Research Center, Inc.

    Fountain Valley, California

  • Valley Research

    Fresno, California

  • Randall Shue, D.O.

    Los Angeles, California

  • Clinical Trials Research

    Roseville, California

  • New West Physicians

    Golden, Colorado

  • Phoenix Internal Medicine Associates, Llc

    Waterbury, Connecticut

  • Christiana Care Research Institute

    Newark, Delaware

  • Central Florida Clinical Trials

    Altamonte Springs, Florida

  • Family Care Assoc & Emerald Care Res Grp

    Chipley, Florida

  • Clinical Therapeutics Corporation

    Coral Gables, Florida

  • Fpa Clinical Research

    Kissimmee, Florida

  • Emerald Coast Research Group

    Marianna, Florida

  • University Of Miami Diabetes Research Inst.

    Miami, Florida

  • Atlanta Pharmaceutical Research Center, Inc

    Dunwoody, Georgia

  • Cedar-Crosse Research Ctr

    Chicago, Illinois

  • Family Medical Center Of Hart Co.

    Munfordville, Kentucky

  • Columbia Medical Practice

    Columbia, Maryland

  • Va Medical Center

    Kansas City, Missouri

  • St. Louis Center For Clinical Research

    St Louis, Missouri

  • Nevada Alliance Against Diabetes

    North Las Vegas, Nevada

  • Physicians Research Center

    Toms River, New Jersey

  • Cny Family Care

    East Syracuse, New York

  • Metrolina Internal Medicine

    Charlotte, North Carolina

  • Med Res Assoc Charlotte

    Charlotte, North Carolina

  • Regional Physicians Research

    High Point, North Carolina

  • Diabetes & Endocrinology Consultants, Pc

    Morehead City, North Carolina

  • Mountain Top Clinical Research Center

    Sparta, North Carolina

  • Daystar Clinical Research, Inc.

    Akron, Ohio

  • Community Health Care

    Canal Fulton, Ohio

  • Triphase Research, Ltd.

    Franklin, Ohio

  • Albert J Weisbrot,Md&Assoc Inc

    Mason, Ohio

  • Dr Bahagwan Dass Md

    Youngstown, Ohio

  • Oklahoma Cardiovascular And Hypertension Center

    Oklahoma City, Oklahoma

  • Utica Park Clinic

    Tulsa, Oklahoma

  • Integris Family Care Yukon

    Yukon, Oklahoma

  • Coordinators Plus, Llc

    Eugene, Oregon

  • Oregon Clinical Research

    Portland, Oregon

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.